ArticleApplied biochemistry and biotechnology2026
Chemopreventive Potential of Brucine-Gold Nanoparticles (BRU-AuNPs) in DMBA-induced Mammary Cancer via Modulation of PI3K/AKT/mTOR Pathway.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the effects of brucine-gold nanoparticles (BRU-AuNPs) on rat mammary carcinogenesis by analysing biochemical, histological, and molecular interactions. Mammary cancer was induced in female Sprague-Dawley rats via subcutaneous injection of a chemical carcinogen (DMBA 25 mg/rat) near the mammary gland. Different concentrations of BRU-AuNPs (0.25, 0.5, and 1 mg/kg b.w) were orally administered for 112 days to assess the optimum dose. Parameters including body weight changes, tumor incidence, tumor volume, and tumor burden were analysed in control and experimental rats. Biochemical analyses include lipid peroxidation, antioxidant status, detoxification enzyme activities, and lipid profiles. Histopathological examinations of mammary tissues were performed to evaluate tissue and cellular integrity. The results revealed that BRU-AuNPs treatment to DMBA-injected rats significantly reduced incidence, tumor weight, and burden, lipid peroxidation, and phase I detoxification enzyme activities. Conversely, it improved body weight, phase II detoxification enzyme activities, and antioxidant status compared to DMBA-alone injected rats. Histopathological findings confirmed the protective effect of BRU-AuNPs against DMBA-induced tissue damage. Furthermore, molecular studies demonstrated that BRU-AuNPs modulate the PI3K/AKT/mTOR pathway by downregulating p-PI3K, p-AKT, and p-mTOR gene expression while upregulating PTEN and PKD1 levels. These molecular alterations were validated through immunohistochemistry and Western blot analyses. In conclusion, BRU-AuNPs exhibit significant anticancer effects by modulating oxidative stress and inhibiting the PI3K/AKT/mTOR pathway. These findings highlight their potential as a promising therapeutic strategy for breast cancer prevention.
Indexed as
Identifiers
41824269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.